Cartesian Therapeutics' 15min chart shows KDJ Death Cross, Bearish Marubozu formation.

Based on the 15-minute chart of Cartesian Therapeutics, a KDJ Death Cross and Bearish Marubozu pattern was observed on August 11, 2025 at 12:30. This indicates a shift in momentum towards the downside and a potential for further price depreciation. The sellers currently dominate the market, and there is a likelihood of continued bearish momentum.

Based on the 15-minute chart of Cartesian Therapeutics (RNAC), a significant bearish signal was observed on August 11, 2025, at 12:30. This signal, characterized by a KDJ Death Cross and Bearish Marubozu pattern, indicates a shift in momentum towards the downside and a potential for further price depreciation. The sellers currently dominate the market, suggesting that bearish momentum is likely to continue.

The KDJ Death Cross, generated by the KDJ indicator, occurs when the K line crosses below the D line, often seen as a bearish signal [1]. This pattern is typically followed by a Bearish Marubozu, a candlestick characterized by a long body with no shadows above or below, indicating strong selling pressure [2]. These signals follow a broader trend of widening Bollinger Bands and KDJ Golden Cross formations observed in several other stocks [2, 3].

While technical indicators provide valuable insights, investors should consider these signals in conjunction with fundamental analysis and broader market conditions. Cartesian Therapeutics released its Q2 2025 earnings on August 7, 2025. The company posted a headline net income result far above expectations, with GAAP earnings per share at $0.51 compared to an estimated ($0.80) loss. However, GAAP revenue for Q2 2025 dropped 99.1% from last year to $0.298 million, driven by the absence of last year's sizable collaboration and license payments [2]. The company's actual operating loss on a GAAP basis, driven by a combination of research and development and administrative expenses, totaled $(21.8) million.

Despite the challenging operational picture, Cartesian Therapeutics continues to make progress in its clinical trials. The pivotal Phase 3 AURORA trial for Descartes-08 in myasthenia gravis started enrolling patients, offering a potential path to registration if successful. The trial's outpatient, chemotherapy-free dosing sets it apart from older DNA-based CAR-T approaches, and earlier Phase 2b data showed promising efficacy and tolerability [2].

Investors should watch for AURORA trial enrollment progress, interim data announcements, and the start of additional trials in lupus and other rare autoimmune diseases. The company's control of a proprietary cGMP facility supports quality assurance and rapid scaling as clinical and potential commercial needs grow [2].

References:
[1] https://www.ainvest.com/news/cartesian-therapeutics-kdj-death-cross-bearish-marubozu-signal-15-minute-chart-2508-24/
[2] https://www.nasdaq.com/articles/cartesian-rnac-q2-revenue-drops-99